Neoplasms
Recent clinical, regulatory, research and industry developments relating to this disease.
Hallmarks of cancer-Then and now, and beyond.
Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors.
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion.
Pyroptosis in cancer therapy: a double-edged sword for immune activation and tumor progression.
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade.
Trained immunity: induction of an inflammatory memory in disease.
Next-gen tools in cancer neuroscience.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q4 2026.
- Active recent publication activity, including 3 notable findings.
- Q4 2026A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
- Q4 2027EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
- Q3 2028A Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)
- Q3 2029A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort
- Q4 203017000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)
Research HighlightsView all 29Hide
- 2026-01-29Hallmarks of cancer-Then and now, and beyond.Hanahan D · 2026
- 2026-01-05Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors.Liu J · 2026
- 2025-12-31Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications.Liu Y · 2026
- 2025-10-22SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade.Grippin AJ · 2025
- 2025-10-14Trained immunity: induction of an inflammatory memory in disease.Schlüter T · 2025
- 2026-01-01Cancer statistics, 2026.Siegel RL · 2026
Clinical MilestonesViewHide
- 2026-07-0717000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)Results expected Q4 2030
- 2026-07-06A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical CystectomyResults expected Q4 2026
- 2026-07-06A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational CohortResults expected Q3 2029
- 2026-05-22A Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)Results expected Q3 2028
- 2026-04-02EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of RecurrenceResults expected Q4 2027
- 2026-07-07Clinical17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)Results expected Q4 2030
- 2026-07-06ClinicalA Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical CystectomyResults expected Q4 2026
- 2026-07-06ClinicalA Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational CohortResults expected Q3 2029
- 2026-06-11ClinicalAN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCERResults posted
- 2026-05-22ClinicalA Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)Results expected Q3 2028
- 2026-04-02ClinicalEMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of RecurrenceResults expected Q4 2027
- 2026-02-05ClinicalA Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA MutationTerminated
- 2026-01-29ResearchHallmarks of cancer-Then and now, and beyond.Hanahan D · 2026
- 2026-01-26ResearchTargeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications.Wang X · 2026
- 2026-01-05ResearchExtracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors.Liu J · 2026
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Carmustine is indicated n adults in the following malignant neoplasms as a single ag… (2018)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Neoplasms862
- Immunotherapy120
- Tumor Microenvironment107
- Immune Checkpoint Inhibitors103
- Antineoplastic Agents45
- Receptors, Chimeric Antigen39
- Immunotherapy, Adoptive31
- Gastrointestinal Microbiome28
Leading journals6
- Frontiers in immunology139
- Molecular cancer102
- Signal transduction and targeted therapy98
- Journal of hematology & oncology72
- International journal of molecular sciences53
- Nature communications46
Leading researchers8
- Zhang Y47
- Wang Y45
- Li Y42
- Wang J36
- Liu Y33
- Li X28
- Liu J28
- Zhang J28
Affiliations (unnormalised)6
- School of Medicine51
- Dana-Farber Cancer Institute46
- The University of Texas MD Anderson Cancer Center45
- Memorial Sloan Kettering Cancer Center39
- Harvard Medical School33
- University of California33
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Neoplasms are abnormal new growths of tissue. They include benign and malignant forms; malignant neoplasms are characterized by greater anaplasia and by invasion and metastasis.
The supplied grounding does not support a specific cause or aetiology for neoplasms as a whole. It does indicate that neoplasms are studied in relation to genetic and epigenetic changes, altered gene expression, and signaling abnormalities.
The grounding supports a broad biology of neoplasia involving abnormal cell growth, invasion, and metastasis. Literature also emphasizes tumor microenvironment effects, signal transduction changes, epithelial-mesenchymal transition, immune escape, apoptosis, and drug resistance as mechanisms relevant to neoplastic behavior.
The supplied grounding does not support specific risk factors for neoplasms as a general category. It does indicate that tumor immune microenvironment features and chronic inflammatory contexts can influence tumor initiation and response to therapy.
The grounding supports treatment at the level of immunotherapy, targeted therapy, and nanomedicine-based drug delivery. It also includes antibody-based approaches, immune checkpoint blockade-related modalities, cytokine-based strategies, chimeric antigen receptor-based therapies, immunoconjugates, and liposome-based formulations.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-06.
Reference
Authoritative identity, definition & identifiers.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.